Vident Investment Advisory LLC decreased its holdings in shares of AstraZeneca plc (NYSE:AZN) by 13.2% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 26,923 shares of the company’s stock after selling 4,091 shares during the quarter. Vident Investment Advisory LLC’s holdings in AstraZeneca were worth $1,424,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wedbush Securities Inc. grew its holdings in shares of AstraZeneca by 7.0% during the second quarter. Wedbush Securities Inc. now owns 11,313 shares of the company’s stock valued at $598,000 after purchasing an additional 739 shares during the last quarter. Global Retirement Partners LLC boosted its position in AstraZeneca by 41.8% during the 2nd quarter. Global Retirement Partners LLC now owns 1,633 shares of the company’s stock valued at $86,000 after purchasing an additional 481 shares during the period. HighTower Advisors LLC acquired a new position in AstraZeneca during the 1st quarter valued at approximately $2,340,000. Trust Co. of Vermont grew its stake in AstraZeneca by 5.2% during the 2nd quarter. Trust Co. of Vermont now owns 4,018 shares of the company’s stock worth $212,000 after buying an additional 200 shares during the last quarter. Finally, TIAA FSB increased its position in AstraZeneca by 59.1% in the second quarter. TIAA FSB now owns 34,769 shares of the company’s stock worth $1,839,000 after buying an additional 12,917 shares during the period. Hedge funds and other institutional investors own 16.84% of the company’s stock.
Several brokerages recently weighed in on AZN. Zacks Investment Research downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating and set a $59.00 price objective on the stock. in a research report on Wednesday. Morgan Stanley reissued an “equal weight” rating on shares of AstraZeneca in a report on Wednesday, May 6th. Barclays restated an “overweight” rating on shares of AstraZeneca in a research report on Wednesday. Guggenheim reiterated a “buy” rating on shares of AstraZeneca in a research report on Friday, May 29th. Finally, Argus raised their price target on AstraZeneca from $54.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Four investment analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. AstraZeneca presently has a consensus rating of “Hold” and an average price target of $61.00.
AZN opened at $55.78 on Friday. The business has a 50 day moving average price of $54.53 and a two-hundred day moving average price of $50.30. The company has a debt-to-equity ratio of 1.32, a current ratio of 0.75 and a quick ratio of 0.57. The company has a market capitalization of $146.39 billion, a price-to-earnings ratio of 28.46, a price-to-earnings-growth ratio of 1.65 and a beta of 0.55. AstraZeneca plc has a 1-year low of $36.15 and a 1-year high of $64.94.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.48 EPS for the quarter, topping the Zacks’ consensus estimate of $0.44 by $0.04. AstraZeneca had a return on equity of 37.83% and a net margin of 8.36%. The company had revenue of $6.28 billion for the quarter, compared to the consensus estimate of $6.27 billion. During the same quarter in the previous year, the business earned $0.73 EPS. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. Equities analysts expect that AstraZeneca plc will post 2.04 EPS for the current fiscal year.
The firm also recently declared a semi-annual dividend, which will be paid on Monday, September 14th. Shareholders of record on Friday, August 14th will be issued a $0.45 dividend. This represents a yield of 2.5%. The ex-dividend date is Thursday, August 13th. AstraZeneca’s payout ratio is 106.29%.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Further Reading: What is Depreciation?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.